Collectively, these findings establish PSG9 as a novel player in breast cancer progressionvia hijacking the canonical TGF‐β/Smad signaling, and identify PSG9 as a potential plasma biomarker for the early detection of breast cancer. Here, PSG9 is linked to breast cancer.